Selective TBK1/IKKi dual inhibitors with anticancer potency

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Noncanonical IKKs (IKKi and TBK1) are implicated in cancer development.
• Targeting these kinases is a promising strategy for cancer therapy.

Purpose of the Study:

• To investigate the necessity of dual TBK1/IKKi inhibition for cancer treatment.
• To develop and evaluate novel dual TBK1/IKKi inhibitors.

Main Methods:

• Development of a novel 2-amino-4-(3'-cyano-4'-pyrrolidine)phenyl-pyrimidine scaffold.
• In vitro assessment of cell viability in human cancer cell lines (breast, prostate, oral).
• In vivo evaluation in xenograft and allograft mouse models.

Main Results:

• Three novel dual TBK1/IKKi inhibitors potently inhibited cancer cell viability.
• Inhibitors significantly impaired tumor development in mouse models.
• Anticancer effects were linked to suppressed AKT phosphorylation and VEGF expression.

Conclusions:

• Simultaneous targeting of TBK1 and IKKi is essential for efficient tumor cell proliferation suppression.
• Developed dual inhibitors exhibit promising anticancer activity and drug-like properties.
• These findings support further drug discovery for novel cancer therapeutics.